WEHI Parkinson’s Disease Special Seminar hosted by Professor Grant Dewson

Matthew Cooper, PhD

Founder and CEO – Sitala Ltd

Infection & innate immunity – from bugs to drugs

L7W Seminar Room

Join via TEAMS

Including Q&A session

Matthew Cooper, PhD is a medical research entrepreneur with a track record of innovation, business development, biotech start ups and products launched to market. He has R&D experience in diagnostics and therapeutics in a wide variety of indications, in particular inflammatory, infectious and neurodegenerative diseases.

He has founded/co-founded 6 companies; including Inflazome that developed a brain penetrant NLRP3 inhibitor (acquired by Roche for $450m and currently in clinical trials including for Parkinson’s). NLRP3-driven inflammation is emerging as an exciting disease modifying target in neurodegenerative disease including Parkinson’s. More recently, he founded Sitala Bio Ltd, which focuses on blocking neuroinflammation and neurodegeneration. He was also the founding Director of the Centre for Superbug Solutions, University of Queensland.

He has received $82 million funding including from Wellcome Trust, Bill & Melinda Gates Foundation, Michael J Fox Foundation and Shake it Up Foundation. He is a Fellow of the Royal Society of Chemistry and recipient of multiple awards including winner of the Ernst & Young Emerging Entrepreneur of the Year Ireland and Ōmura Japan Medal.

All welcome!